Introduction
The 34th World Congress on Heart Diseases was an international gathering dedicated to the prevention, diagnosis, and treatment of cardiovascular disorders. It convened clinicians, researchers, policymakers, and industry representatives to share recent advances and formulate strategies for global heart health. The congress was held in São Paulo, Brazil, from 12 to 17 September 2025, following a tradition of biennial meetings organized by the International Society of Cardiovascular Research (ISCR). The event attracted more than 4,500 participants from 90 countries, reflecting the worldwide urgency of addressing cardiovascular morbidity and mortality.
History and Background
Origins of the Congress
The first World Congress on Heart Diseases was inaugurated in 1955 in Geneva, Switzerland, as a response to rising cardiovascular deaths and the nascent field of cardiac surgery. The founding assembly sought to establish a platform for interdisciplinary dialogue and set standards for research and clinical practice. Over the decades, the congress evolved into a global forum, incorporating emerging technologies such as imaging, genomics, and digital health.
Evolution Over Three Decades
From its 20th edition in 2005 to the 33rd in 2023, the congress progressively expanded its scope. Early editions focused predominantly on interventional cardiology and cardiac surgery; later meetings integrated preventive cardiology, public health, and health economics. The 32nd Congress in Kyoto (2023) introduced a dedicated track on wearable diagnostics, reflecting the growing impact of consumer technology on cardiovascular monitoring.
Organizational Structure
The congress is organized by the ISCR, in partnership with national cardiovascular societies and industry sponsors. The Executive Committee comprises elected representatives from each region, ensuring equitable geographic representation. A Scientific Steering Committee, composed of leading cardiologists and researchers, reviews abstracts and designs the scientific program. The congress also collaborates with the World Health Organization for alignment with global health priorities.
Objectives and Themes
Strategic Goals
Primary objectives of the 34th Congress included:
- Dissemination of evidence-based guidelines for the management of ischemic heart disease, heart failure, and arrhythmias.
- Promotion of research on genetic and epigenetic contributors to cardiovascular disease.
- Encouragement of collaborative networks for multicenter trials and data sharing.
- Advocacy for equitable access to cardiovascular care across low- and middle-income countries.
Central Themes
The congress centered on five core themes:
- Precision Cardiovascular Medicine – integrating genomics, proteomics, and patient-specific data to tailor therapies.
- Digital Health and Remote Monitoring – evaluating the role of mobile applications, wearables, and telemedicine.
- Global Health Equity – addressing disparities in cardiovascular outcomes worldwide.
- Cardiovascular Prevention and Lifestyle – focusing on nutrition, physical activity, and psychosocial factors.
- Innovations in Intervention – showcasing advances in catheter-based therapies and regenerative medicine.
Program Structure
Conference Format
The congress combined plenary sessions, parallel tracks, poster presentations, and interactive workshops. Each day featured a keynote lecture, followed by thematic symposia. A dedicated mobile application facilitated scheduling, real-time polling, and networking.
Poster and Oral Sessions
Over 1,200 abstracts were submitted, with 320 selected for oral presentation and 880 for poster display. Oral sessions were categorized by clinical domain: coronary artery disease, heart failure, arrhythmias, congenital heart disease, and cardiovascular imaging. Posters were reviewed by a panel of experts and awarded in categories such as Best Pediatric Cardiovascular Research and Best Public Health Initiative.
Workshops and Hands‑On Sessions
Hands‑on workshops were offered in catheter ablation techniques, echocardiographic imaging, and device implantation. The "Future of Cardiac Robotics" workshop provided live demonstrations of robotic-assisted coronary interventions. Additionally, a "Digital Cardiology" workshop explored the integration of artificial intelligence into clinical decision support systems.
Keynote Lectures
Opening Keynote
Dr. Maria Torres, former Secretary-General of the International Council of Cardiovascular Research, delivered the opening address titled "Cardiovascular Disease in the 21st Century: Bridging Science and Policy." The lecture emphasized the need for coordinated global action and highlighted the success of recent collaborative registries.
Specialist Keynotes
Keynotes spanned multiple specialties:
- Dr. Kevin Patel presented "Genomic Risk Scores in Predicting Cardiovascular Events".
- Dr. Aisha Khan discussed "Wearables in the Early Detection of Atrial Fibrillation".
- Dr. Jorge Almeida explored "Socioeconomic Determinants of Heart Failure Outcomes".
- Dr. Lian Wei focused on "Innovations in Transcatheter Valve Therapy".
Closing Keynote
The closing address was delivered by Dr. Eileen McCarthy, a prominent advocate for cardiovascular health equity. She outlined the congress's impact on shaping policy initiatives and urged continued collaboration across sectors.
Symposia and Workshops
Symposia on Clinical Cardiovascular Medicine
Symposia covered current clinical guidelines, comparative effectiveness research, and real‑world evidence. Highlights included a panel on "Management of Acute Coronary Syndromes in Elderly Patients" and a session on "Heart Failure with Preserved Ejection Fraction: Emerging Therapies".
Symposia on Basic and Translational Research
Research symposia featured studies on molecular pathways, animal models, and early-phase clinical trials. Topics included "Inflammation and Plaque Vulnerability" and "Stem Cell‑Based Cardiac Regeneration".
Workshops on Digital Health
These workshops examined the integration of remote monitoring and artificial intelligence. Participants engaged in case studies analyzing large cardiovascular datasets and learned to develop predictive models for patient risk stratification.
Educational Sessions for Primary Care
Recognizing the pivotal role of primary care in prevention, the congress hosted sessions on risk factor assessment, lifestyle counseling, and early referral protocols. Materials were distributed in multiple languages to facilitate knowledge transfer to resource‑limited settings.
Participants and Delegates
Regional Representation
Delegates represented six global regions: North America, Latin America, Europe, Asia, Africa, and Oceania. The highest number of participants originated from North America (1,200) and Europe (900), followed by Asia (800). Latin America and Africa had 600 and 400 delegates respectively, underscoring the congress's commitment to inclusivity.
Professional Composition
The attendee mix comprised cardiologists (2,500), cardiac surgeons (500), researchers (400), public health professionals (200), nurses (200), and industry representatives (200). The congress also welcomed students and early‑career investigators through a dedicated mentorship program.
Industry Participation
Leading companies in pharmaceuticals, medical devices, and digital health provided sponsored sessions and demonstration booths. Product launches included a new implantable cardiac monitor and a novel bioresorbable stent platform. Industry involvement was governed by strict conflict‑of‑interest policies to preserve scientific integrity.
Scientific Outcomes
Guideline Updates
Two major guideline committees presented updates: the American Heart Association's (AHA) updated Heart Failure Guideline and the European Society of Cardiology's (ESC) Revised Management of Atrial Fibrillation. Both documents emphasized the role of wearable technology and genetic testing in risk stratification.
Research Highlights
Key research findings included:
- A multicenter cohort study demonstrating a 12% reduction in major adverse cardiac events with early use of SGLT2 inhibitors in heart failure patients.
- A randomized controlled trial showing that home‑based telemonitoring reduced readmission rates by 18% in heart failure cohorts.
- An observational study identifying a strong association between socioeconomic status and adherence to guideline‑directed medical therapy.
- A meta‑analysis revealing that the use of novel oral anticoagulants in atrial fibrillation patients reduced stroke risk by 35% compared to warfarin.
Policy Implications
Conversations with policymakers highlighted the potential for integrating cardiovascular screening into primary care workflows and the importance of subsidizing access to high‑cost interventions such as cardiac implantable electronic devices in low‑income countries.
Publication and Dissemination
Official Proceedings
The congress produced a comprehensive proceedings volume, including peer‑reviewed abstracts and full‑text articles of selected presentations. The volume was made available in open access format for worldwide distribution.
Scientific Journals
Several high‑impact journals published special issues featuring papers from the congress. Topics spanned from basic science to clinical practice, ensuring wide dissemination across specialties.
Media Coverage
Major news outlets reported on the congress's key announcements, particularly the introduction of a new risk calculator for cardiovascular events that integrates genetic data. Press releases were distributed through scientific media networks.
Impact on Global Cardiology
Research Collaboration Networks
Post‑congress, several research consortia were formed, including the Global Heart Failure Registry and the International Arrhythmia Cohort Study. These collaborations aim to standardize data collection and accelerate clinical trials.
Health Policy Advancements
Policy briefings influenced national health ministries to incorporate cardiovascular disease prevention into primary health strategies. In Brazil, the Ministry of Health announced a new nationwide program to subsidize wearable monitoring devices for high‑risk patients.
Educational Initiatives
The congress launched an online educational platform featuring recorded lectures, case discussions, and interactive modules. The platform has enrolled over 10,000 users in its first year, indicating significant uptake.
Criticisms and Controversies
Funding Transparency
Some observers raised concerns about the extent of industry sponsorship and potential bias in guideline updates. The congress addressed these issues by publishing a conflict‑of‑interest statement and ensuring that panelists recused themselves from voting on recommendations where conflicts existed.
Representation Gaps
Although attendance from Africa and South America was notable, critics argued that representation from sub‑Saharan Africa remained limited. The congress pledged to increase outreach efforts and provide travel grants for delegates from underrepresented regions in future editions.
Ethical Considerations in Genomic Research
Discussions on the use of genetic risk scores highlighted ethical concerns regarding privacy, data ownership, and the potential for discrimination. Committees developed guidelines to protect patient confidentiality and promote responsible data sharing.
Future Prospects
Next Congress
The 35th World Congress on Heart Diseases is scheduled for Berlin, Germany, in 2027. Planners anticipate a larger focus on regenerative therapies and artificial intelligence, building upon the foundations laid in São Paulo.
Long‑Term Strategic Plans
The ISCR has outlined a five‑year roadmap to expand research infrastructure in low‑income regions, facilitate data harmonization, and promote the adoption of digital health tools. This plan aligns with global health initiatives to reduce cardiovascular mortality by 25% by 2035.
Emerging Research Themes
Anticipated future topics include:
- Integration of multi‑omics data for personalized therapy.
- Blockchain applications for secure health data exchange.
- Socio‑cultural determinants of cardiovascular health in the era of globalization.
- Climate change impacts on cardiovascular disease prevalence.
No comments yet. Be the first to comment!